OptimizeRx Co. (NASDAQ:OPRX) Shares Bought by Squarepoint Ops LLC

Squarepoint Ops LLC lifted its position in shares of OptimizeRx Co. (NASDAQ:OPRX - Free Report) by 298.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 41,712 shares of the company's stock after buying an additional 31,252 shares during the quarter. Squarepoint Ops LLC owned approximately 0.23% of OptimizeRx worth $203,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in OPRX. SBI Securities Co. Ltd. purchased a new stake in shares of OptimizeRx in the fourth quarter valued at $25,000. SG Americas Securities LLC acquired a new position in OptimizeRx in the 4th quarter valued at about $51,000. Wells Fargo & Company MN lifted its holdings in OptimizeRx by 33.3% in the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after purchasing an additional 2,797 shares in the last quarter. Graham Capital Management L.P. purchased a new position in OptimizeRx in the 4th quarter valued at about $81,000. Finally, BNP Paribas Financial Markets grew its holdings in shares of OptimizeRx by 504.6% during the fourth quarter. BNP Paribas Financial Markets now owns 22,308 shares of the company's stock worth $108,000 after buying an additional 18,618 shares in the last quarter. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

OPRX has been the subject of several analyst reports. B. Riley reiterated a "buy" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Stifel Nicolaus lifted their price objective on OptimizeRx from $8.00 to $12.50 and gave the company a "buy" rating in a research report on Tuesday, May 13th. JMP Securities increased their target price on OptimizeRx from $11.00 to $14.00 and gave the stock a "market outperform" rating in a research report on Tuesday, May 13th. Roth Capital restated a "buy" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Finally, Citigroup reiterated an "outperform" rating on shares of OptimizeRx in a report on Tuesday, May 13th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $10.38.

OptimizeRx Stock Up 3.1%

Shares of NASDAQ:OPRX opened at $14.62 on Monday. The company has a market capitalization of $270.40 million, a price-to-earnings ratio of -10.99 and a beta of 1.34. The company has a 50 day moving average of $9.98 and a two-hundred day moving average of $7.26. OptimizeRx Co. has a 52-week low of $3.78 and a 52-week high of $15.25. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $0.08 earnings per share for the quarter, beating analysts' consensus estimates of ($0.11) by $0.19. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. The business had revenue of $21.93 million during the quarter, compared to analyst estimates of $18.69 million. As a group, analysts forecast that OptimizeRx Co. will post -0.33 earnings per share for the current fiscal year.

Insider Buying and Selling

In other OptimizeRx news, Director James Paul Lang acquired 321,408 shares of the stock in a transaction on Friday, March 14th. The stock was purchased at an average price of $7.60 per share, for a total transaction of $2,442,700.80. Following the purchase, the director now directly owns 389,452 shares in the company, valued at $2,959,835.20. This trade represents a 472.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 5.60% of the company's stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

Want to see what other hedge funds are holding OPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptimizeRx Co. (NASDAQ:OPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.